Australia To Speed Up Post-Market Reviews Of Reimbursed Drugs
Executive Summary
The existing framework for assessing whether medicines should continue to be reimbursed is no longer fit for purpose and requires an overhaul if the ongoing viability of the Pharmaceutical Benefits Scheme is to be ensured, says Australia’s health department.